Author

Li Bai

Observed institutions: Army Medical University, Fudan University, Chinese PLA General Hospital, Xinqiao Hospital, Zhongshan Hospital, Chinese People's Liberation Army

ORCID: 0000-0002-6283-986X

Observed ORCID: 0000-0002-6283-986X

OpenAlex ID: A5111485930

Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial

2016 · Jifang Gong, Tianshu Liu, et al. · BMC Cancer · 97

PDF

First‐line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis

2022 · Tianshu Liu, Yuxian Bai, et al. · International Journal of Cancer · 71

PDF

A Classifier for Improving Early Lung Cancer Diagnosis Incorporating Artificial Intelligence and Liquid Biopsy

2022 · Maosong Ye, Lin Tong, et al. · Frontiers in Oncology · 44

PDF

Efficacy and safety for Apatinib treatment in advanced gastric cancer: a real world study

2017 · Yong Zhang, Chun Han, et al. · Scientific Reports · 39

PDF

Assessment of the cancer risk factors of solitary pulmonary nodules

2017 · Li Yang, Qiao Zhang, et al. · Oncotarget · 35

PDF

Circulating tumor cells in early stage lung adenocarcinoma: a case series report and literature review

2017 · Xu-Rui Jin, Lu-Yao Zhu, et al. · Oncotarget · 34

PDF

International expert consensus on diagnosis and treatment of lung cancer complicated by chronic obstructive pulmonary disease

2023 · Chengzhi Zhou, Yinyin Qin, et al. · Translational Lung Cancer Research · 33

PDF

Association between Th17‐related cytokines and risk of non–small cell lung cancer among patients with or without chronic obstructive pulmonary disease

2015 · Chen Liao, Zu-Bin Yu, et al. · Cancer · 26

PDF

Suppression of Akt1 phosphorylation by adenoviral transfer of the PTEN gene inhibits hypoxia-induced proliferation of rat pulmonary arterial smooth muscle cells

2010 · Chunxia Luo, Bin Yi, et al. · Biochemical and Biophysical Research Communications · 26

Prognostic and predictive significance of thymidylate synthase protein expression in non-small cell lung cancer: A systematic review and meta-analysis

2015 · Qingyun Liu, Zubin Yu, et al. · Cancer Biomarkers · 20

PDF

cGMP-dependent protein kinase Iα transfection inhibits hypoxia-induced migration, phenotype modulation and annexins A1 expression in human pulmonary artery smooth muscle cells

2012 · Bin Yi, Jian Cui, et al. · Biochemical and Biophysical Research Communications · 15

Efficacy and safety of apatinib as second-line therapy for advanced gastric cancer

2017 · Yong Zhang, Miaomiao Gou, et al. · Anti-Cancer Drugs · 10

Criteria for lung cancer screening and standardized management in China

2023 · Qi Wang, Xiaoju Zhang, et al. · Chinese Medical Journal · 7

Abstract CT184: First-Line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis

2021 · Lin Shen, Yuxian Bai, et al. · Cancer Research · 7

Retrospective Evaluation of the Efficacy of First-Line Treatment of Advanced Gastric Cancer With Docetaxel and Oxaliplatin

2014 · Zhi-yuan Mao, Xiao-chuan Guo, et al. · Cancer Investigation · 4

A multicenter, phase II study of trastuzumab plus capecitabine and oxaliplatin (XELOX) as first-line chemotherapy for HER2-positive advanced gastric cancer: Update results of efficacy and toxicity.

2014 · Jifang Gong, Tianshu Liu, et al. · Journal of Clinical Oncology · 3

The Chinese subgroup from a randomized phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone as second-line treatment of HER2-amplified advanced gastric cancer (AGC) in Asian countries.

2013 · Guo-ping Sun, Yan Sun, et al. · Journal of Clinical Oncology · 3

First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis 4-year (yr) follow-up.

2024 · Lin Shen, Yuxian Bai, et al. · Journal of Clinical Oncology · 2

PDF

MS4A15 gene expression as a prognostic marker for clinical outcomes in lung adenocarcinoma

2024 · Lingxiao Qiu, Tingcheng Li, et al. · Translational Lung Cancer Research · 1

Macrophage-Associated Genes for Predicting Prognosis and the Tumor Microenvironment in Patients with Hepatocellular Carcinoma.

2023 · Zhiyuan Mao, Yinglin Li, et al. · PubMed · 1

Immune aging and pulmonary diseases

2023 · Liang Guo, Yu Xu, et al. · Clinical eHealth · 1

Clinical characteristics and prognostic outcomes in KRAS-mutant non-small cell lung cancer: A real-world study with or without COPD comorbidity

2025 · Chen Liao, Yubo Wang, et al. · Cancer Treatment and Research Communications

MS4A15 is a novel prognostic biomarker and a potential target in lung adenocarcinoma

2024 · Lingxiao Qiu, Zhi Xu, et al. · Lung Cancer

A phase III trial (ZJBIO009): CMAB009 plus irinotecan versus irinotecan alone as second-line treatment after fluoropyrimidine and oxaliplatin failure in wild-type K-ras metastatic colorectal cancer patients.

2017 · Yuankai Shi, Jin Li, et al. · Journal of Clinical Oncology

[Chemotherapy and targeted therapy in liver metastasis from gastric cancer].

2014 · Dan Su, Li Bai · PubMed

Works count: 26

Citation count: 478

H-index: 11

I10-index: 12